Intestinal polyps electronic colon endoscopic image auxiliary detection software is approved for listing

Recently, the State Drug Administration was reviewed and approved the "intestinal polyps electronic colon endoscopic image auxiliary detection software" for innovative products produced by Chengdu Micro -Institution Medical Equipment Co., Ltd.

This product is provided in the form of a CD and is installed and used in a single machine. It has 9 major functional modules of collecting card management, authorization management, drawing detection area, sound prompts, display options, display software information, monitoring operation time, processing algorithm management, and main program. The product only uses the designated electronic colon endoscopy in the medical institution to use it for practicing doctors to display the doubtful polyps in real time when the adult colon endoscopy is checked. This information is for reference only, and doctors should conduct clinical decisions in combination with patients.

The working principle of this product is to import video images in the video signal output port of the endoscopic image processor. After software processing and algorithm analysis, find out the position of suspected polyps and display it in a separate display. This product is the first domestic medical equipment software to use deep learning technology to assist the polyps in the endoscopic image. It uses small sample deep learning technology and local labeling technology to select and develop the algorithm model framework. The overall performance of the algorithm is not not Relying on the increase of training data, it can achieve high performance, boonomability and robustness in smaller samples.

This product is used with electronic colon endoscopy to help doctors find out the position of suspected polyps during colonoscopy, which is conducive to the pre -cancer lesions of rectal cancer earlier, thereby reducing the incidence and mortality of rectal cancer.

The drug supervision and management department will strengthen the supervision of the product after listing to protect the safety of patients.

Source: National Drug Administration

- END -